Novel 2-methyl-5-quinolinyl-1-piperazinylalkyl-3, 4-dihydro-2H-1, 4-benzoxazin-3-ones showing high affinities for the 5-HT1A/1B/1D receptors coupled with potent 5-HT reuptake inhibitory activity have been discovered. This is the first report describing docking of the lead compound 6-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl] ethyl}-2H-1, 4-benzoxazin-3 (4H)- one 1, into a model of the 5-HT transporter and the 5-HT1A receptor model.